Mineralocorticoid receptor in adipocytes and macrophages: A promising target to fight metabolic syndrome

Steroids

Volumn 91, Issue , 2014, Pages 46-53

  Marzolla, Vincenzo ^a   Armani, Andrea ^a   Feraco, Alessandra ^a   De Martino, Massimo U ^b   Fabbri, Andrea ^c   Rosano, Giuseppe ^a   Caprio, Massimiliano ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adipocyte; Adipose tissue; Insulin resistance; Macrophage; Mineralocorticoid receptor

Indexed keywords

MINERALOCORTICOID RECEPTOR;

ADIPOCYTE; ANIMAL; BIOLOGICAL MODEL; HUMAN; MACROPHAGE; METABOLIC SYNDROME X; METABOLISM; MOLECULARLY TARGETED THERAPY;

ADIPOCYTES; ANIMALS; HUMANS; MACROPHAGES; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, MINERALOCORTICOID;

EID: 84908665580     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.05.001     Document Type: Review

References (96)

1. G.P. Chrousos Stress and disorders of the stress system Nat Rev Endocrinol 5 2009 374 381
2. J.W. Funder Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance Annu Rev Med 48 1997 231 240
3. G. Di Dalmazi, U. Pagotto, R. Pasquali, and V. Vicennati Glucocorticoids and type 2 diabetes: from physiology to pathology J Nutr Metab 2012 2012 525093
4. S.J. Pilkis, and D.K. Granner Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis Annu Rev Physiol 54 1992 885 909
5. M. Boscaro, G. Giacchetti, and V. Ronconi Visceral adipose tissue: emerging role of gluco-and mineralocorticoid hormones in the setting of cardiometabolic alterations Ann N Y Acad Sci 1264 2012 87 102
6. J.T. Bridgham, S.M. Carroll, and J.W. Thornton Evolution of hormone-receptor complexity by molecular exploitation Science 312 2006 97 101
7. G.P. Chrousos, and T. Kino Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders Ann N Y Acad Sci 1179 2009 153 166
8. N. Farman, and M.E. Rafestin-Oblin Multiple aspects of mineralocorticoid selectivity Am J Physiol Renal Physiol 280 2001 F181 F192
9. B. Chantong, D.V. Kratschmar, L.G. Nashev, Z. Balazs, and A. Odermatt Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells J Neuroinflammation 9 2012 260
10. J.W. Conn Hypertension, the potassium ion and impaired carbohydrate tolerance N Engl J Med 273 1965 1135 1143
11. K. Shimamoto, M. Shiiki, T. Ise, Y. Miyazaki, K. Higashiura, M. Fukuoka, A. Hirata, A. Masuda, M. Nakagawa, and O. Iimura Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8 1994 755 759
12. F. Fallo, F. Veglio, C. Bertello, N. Sonino, M.P. Della, M. Ermani, F. Rabbia, G. Federspil, and P. Mulatero Prevalence and characteristics of the metabolic syndrome in primary aldosteronism J Clin Endocrinol Metab 91 2006 454 459
13. V. Ronconi, F. Turchi, G. Appolloni, V. di T, M. Boscaro, and G. Giacchetti Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists Curr Vasc Pharmacol 10 2012 238 246
14. E. Ingelsson, M.J. Pencina, G.H. Tofler, E.J. Benjamin, K.J. Lanier, P.F. Jacques, C.S. Fox, J.B. Meigs, D. Levy, M.G. Larson, J. Selhub, R.B. D'Agostino Sr., T.J. Wang, and R.S. Vasan Multi marker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study Circulation 116 2007 984 992
15. C. Dall'Asta, P. Vedani, P. Manunta, P. Pizzocri, M. Marchi, M. Paganelli, F. Folli, and A.E. Pontiroli Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity Nutr Metab Cardiovasc Dis 19 2009 110 114
16. C.A. Northcott, G.D. Fink, H. Garver, J.R. Haywood, E.L. Laimon-Thomson, J.L. McClain, P.W. Pires, W.E. Rainey, C.S. Rigsby, and A.M. Dorrance The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity Endocrinology 153 2012 1764 1773
17. V. Marzolla, A. Armani, M.C. Zennaro, F. Cinti, C. Mammi, A. Fabbri, G.M. Rosano, and M. Caprio The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism Mol Cell Endocrinol 350 2012 281 288
18. M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven, J. Langenbach, H.S. Willenberg, A. Barthel, H. Hauner, S.M. McCann, W.A. Scherbaum, and S.R. Bornstein Human adipocytes secrete mineralocorticoid-releasing factors Proc Natl Acad Sci U S A 100 2003 14211 14216
19. A.M. Briones, C.A. Nguyen Dinh, G.E. Callera, A. Yogi, D. Burger, Y. He, J.W. Correa, A.M. Gagnon, C.E. Gomez-Sanchez, E.P. Gomez-Sanchez, A. Sorisky, T.C. Ooi, M. Ruzicka, K.D. Burns, and R.M. Touyz Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction Hypertension 59 2012 1069 1078
20. C. Guo, V. Ricchiuti, B.Q. Lian, T.M. Yao, P. Coutinho, J.R. Romero, J. Li, G.H. Williams, and G.K. Adler Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines Circulation 117 2008 2253 2261
21. A. Hirata, N. Maeda, A. Hiuge, T. Hibuse, K. Fujita, T. Okada, S. Kihara, T. Funahashi, and I. Shimomura Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice Cardiovasc Res 84 2009 164 172
22. Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, Carpinelli G, Canese R, Pagotto U, Quarta C, Malorni W, Matarrese P, Marconi M, Rosano G, Fabbri A, Young MJ, Caprio M. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high fat diet-fed mice. FASEB J 2014 [Epub ahead of print].
23. T. Homma, M. Fujisawa, K. Arai, M. Ishii, T. Sada, and M. Ikeda Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome J Vet Med Sci 74 2012 1015 1022
24. B. Pitt Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies Mol Cell Endocrinol 217 2004 53 58
25. B. Pitt, N. Reichek, R. Willenbrock, F. Zannad, R.A. Phillips, B. Roniker, J. Kleiman, S. Krause, D. Burns, and G.H. Williams Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 2003 1831 1838
26. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
27. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
28. U. Fuhrmann, R. Krattenmacher, E.P. Slater, and K.H. Fritzemeier The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential Contraception 54 1996 243 251
29. W.B. White, B. Pitt, R.A. Preston, and V. Hanes Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension Circulation 112 2005 1979 1984
30. W.B. White, V. Hanes, V. Chauhan, and B. Pitt Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension Hypertension 48 2006 246 253
31. R.A. Preston, P.M. Norris, A.B. Alonso, P. Ni, V. Hanes, and A.H. Karara Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide Menopause 14 2007 408 414
32. W. Oelkers, J.M. Foidart, N. Dombrovicz, A. Welter, and R. Heithecker Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism J Clin Endocrinol Metab 80 1995 1816 1821
33. D.F. Archer, I.H. Thorneycroft, M. Foegh, V. Hanes, M.D. Glant, P. Bitterman, and R.L. Kempson Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial Menopause 12 2005 716 727
34. J.M. Foidart, and T. Faustmann Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen Gynecol Endocrinol 23 2007 692 699
35. L.B. Tanko, and C. Christiansen Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women J Intern Med 258 2005 544 553
36. M. Caprio, A. Antelmi, G. Chetrite, A. Muscat, C. Mammi, V. Marzolla, A. Fabbri, M.C. Zennaro, and B. Feve Anti adipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome Endocrinology 152 2011 113 125
37. L. Parkin, K. Sharples, R.K. Hernandez, and S.S. Jick Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database BMJ 342 2011 d2139
38. S.S. Jick, and R.K. Hernandez Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data BMJ 342 2011 d2151
39. D. Preiss, S. Zetterstrand, J.J. McMurray, J. Ostergren, E.L. Michelson, C.B. Granger, S. Yusuf, K. Swedberg, M.A. Pfeffer, H.C. Gerstein, and N. Sattar Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program Diabetes Care 32 2009 915 920
40. A.W. Krug, L. Stelzner, A.D. Rao, A.H. Lichtman, G.H. Williams, and G.K. Adler Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males Metabolism 62 2013 386 391
41. R. Garg, L. Kneen, G.H. Williams, and G.K. Adler Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects Diabetes Obes Metab 16 2013 268 272
42. G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, A. D'Angelo, E. Fogari, and P. Maffioli Effects of canrenone in patients with metabolic syndrome Expert Opin Pharmacother 14 2013 2161 2169
43. H. Hauner, G. Entenmann, M. Wabitsch, D. Gaillard, G. Ailhaud, R. Negrel, and E.F. Pfeiffer Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium J Clin Invest 84 1989 1663 1670
44. C.M. Rondinone, D. Rodbard, and M.E. Baker Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes Endocrinology 132 1993 2421 2426
45. M. Caprio, B. Feve, A. Claes, S. Viengchareun, M. Lombes, and M.C. Zennaro Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis FASEB J 21 2007 2185 2194
46. Armani A, Marzolla V, Rosano G, Caprio M. Mineralocorticoid vs glucocorticoid receptors: solo players or team mates in the control of adipogenesis? Int J Obes 2014 [Epub ahead of print].
47. A.R. Saltiel, and C.R. Kahn Insulin signalling and the regulation of glucose and lipid metabolism Nature 414 2001 799 806
48. M.L. Hribal, F. Oriente, and D. Accili Mouse models of insulin resistance Am J Physiol Endocrinol Metab 282 2002 E977 E981
49. E. Arner, M. Ryden, and P. Arner Tumor necrosis factor alpha and regulation of adipose tissue N Engl J Med 362 2010 1151 1153
50. K.E. Wellen, and G.S. Hotamisligil Inflammation, stress, and diabetes J Clin Invest 115 2005 1111 1119
51. M. Jernas, J. Palming, K. Sjoholm, E. Jennische, P.A. Svensson, B.G. Gabrielsson, M. Levin, A. Sjogren, M. Rudemo, T.C. Lystig, B. Carlsson, L.M. Carlsson, and M. Lonn Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression FASEB J 20 2006 1540 1542
52. T. Skurk, C. Alberti-Huber, C. Herder, and H. Hauner Relationship between adipocyte size and adipokine expression and secretion J Clin Endocrinol Metab 92 2007 1023 1033
53. P.E. Scherer, S. Williams, M. Fogliano, G. Baldini, and H.F. Lodish A novel serum protein similar to C1q, produced exclusively in adipocytes J Biol Chem 270 1995 26746 26749
54. A.H. Berg, T.P. Combs, and P.E. Scherer ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism Trends Endocrinol Metab 13 2002 84 89
55. E. Kuhn, C. Bourgeois, V. Keo, S. Viengchareun, A. Muscat, G. Meduri, M.D. Le, B. Feve, and M. Lombes Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice Am J Physiol Endocrinol Metab 306 2014 E75 E90
56. D. Le Menuet, S. Viengchareun, M. Muffat-Joly, M.C. Zennaro, and M. Lombes Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models Mol Cell Endocrinol 217 2004 127 136
57. M.L. Tuck, J. Sowers, L. Dornfeld, G. Kledzik, and M. Maxwell The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients N Engl J Med 304 1981 930 933
58. A. Feraco, A. Armani, C. Mammi, A. Fabbri, G.M. Rosano, and M. Caprio Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity J Steroid Biochem Mol Biol 137 2013 99 106
59. A.W. Krug, K. Vleugels, S. Schinner, V. Lamounier-Zepter, C.G. Ziegler, S.R. Bornstein, and M. Ehrhart-Bornstein Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells Int J Obes (Lond) 31 2007 1605 1616
60. J.H. Jeon, K.Y. Kim, J.H. Kim, A. Baek, H. Cho, Y.H. Lee, J.W. Kim, D. Kim, S.H. Han, J.S. Lim, D.Y. Yoon, S.H. Kim, G.T. Oh, E. Kim, and Y. Yang A novel adipokine CTRP1 stimulates aldosterone production FASEB J 22 2008 1502 1511
61. K. Vleugels, S. Schinner, D. Krause, H. Morawietz, S.R. Bornstein, M. Ehrhart-Bornstein, and A.W. Krug ERK1/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokine-mediated aldosterone secretion Exp Clin Endocrinol Diabetes 119 2011 644 648
62. M. Caprio, B.G. Newfell, S.A. La, W. Baur, A. Fabbri, G. Rosano, M.E. Mendelsohn, and I.Z. Jaffe Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion Circ Res 102 2008 1359 1367
63. -/- mice Endocrinology 152 2011 236 246
64. R.S. Ahima, and J.S. Flier Adipose tissue as an endocrine organ Trends Endocrinol Metab 11 2000 327 332
65. P. Seale, S. Kajimura, and B.M. Spiegelman Transcriptional control of brown adipocyte development and physiological function-of mice and men Genes Dev 23 2009 788 797
66. B.B. Lowell, and B.M. Spiegelman Towards a molecular understanding of adaptive thermogenesis Nature 404 2000 652 660
67. K. Inokuma, Y. Ogura-Okamatsu, C. Toda, K. Kimura, H. Yamashita, and M. Saito Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue Diabetes 54 2005 1385 1391
68. B. Cousin, S. Cinti, M. Morroni, S. Raimbault, D. Ricquier, L. Penicaud, and L. Casteilla Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization J Cell Sci 103 Pt 4 1992 931 942
69. P. Young, J.R. Arch, and M. Ashwell Brown adipose tissue in the parametrial fat pad of the mouse FEBS Lett 167 1984 10 14
70. C. Guerra, R.A. Koza, H. Yamashita, K. Walsh, and L.P. Kozak Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity J Clin Invest 102 1998 412 420
71. K.I. Stanford, R.J. Middelbeek, K.L. Townsend, D. An, E.B. Nygaard, K.M. Hitchcox, K.R. Markan, K. Nakano, M.F. Hirshman, Y.H. Tseng, and L.J. Goodyear Brown adipose tissue regulates glucose homeostasis and insulin sensitivity J Clin Invest 123 2013 215 223
72. A.M. Cypess, S. Lehman, G. Williams, I. Tal, D. Rodman, A.B. Goldfine, F.C. Kuo, E.L. Palmer, Y.H. Tseng, A. Doria, G.M. Kolodny, and C.R. Kahn Identification and importance of brown adipose tissue in adult humans N Engl J Med 360 2009 1509 1517
73. M. Saito, Y. Okamatsu-Ogura, M. Matsushita, K. Watanabe, T. Yoneshiro, J. Nio-Kobayashi, T. Iwanaga, M. Miyagawa, T. Kameya, K. Nakada, Y. Kawai, and M. Tsujisaki High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity Diabetes 58 2009 1526 1531
74. W.D. van Marken Lichtenbelt, J.W. Vanhommerig, N.M. Smulders, J.M. Drossaerts, G.J. Kemerink, N.D. Bouvy, P. Schrauwen, and G.J. Teule Cold-activated brown adipose tissue in healthy men N Engl J Med 360 2009 1500 1508
75. K.A. Virtanen, M.E. Lidell, J. Orava, M. Heglind, R. Westergren, T. Niemi, M. Taittonen, J. Laine, N.J. Savisto, S. Enerback, and P. Nuutila Functional brown adipose tissue in healthy adults N Engl J Med 360 2009 1518 1525
76. M.C. Zennaro, M.D. Le, S. Viengchareun, F. Walker, D. Ricquier, and M. Lombes Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action J Clin Invest 101 1998 1254 1260
77. P. Penfornis, S. Viengchareun, M.D. Le, F. Cluzeaud, M.C. Zennaro, and M. Lombes The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes Am J Physiol Endocrinol Metab 279 2000 E386 E394
78. S. Viengchareun, P. Penfornis, M.C. Zennaro, and M. Lombes Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes Am J Physiol Endocrinol Metab 280 2001 E640 E649
79. T. Wada, H. Kenmochi, Y. Miyashita, M. Sasaki, M. Ojima, M. Sasahara, D. Koya, H. Tsuneki, and T. Sasaoka Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet Endocrinology 151 2010 2040 2049
80. J. Lee Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes Arch Pharm Res 36 2013 208 222
81. A. Chawla, K.D. Nguyen, and Y.P. Goh Macrophage-mediated inflammation in metabolic disease Nat Rev Immunol 11 2011 738 749
82. C.N. Lumeng, J.L. Bodzin, and A.R. Saltiel Obesity induces a phenotypic switch in adipose tissue macrophage polarization J Clin Invest 117 2007 175 184
83. J.I. Odegaard, R.R. Ricardo-Gonzalez, E.A. Red, D. Vats, C.R. Morel, M.H. Goforth, V. Subramanian, L. Mukundan, A.W. Ferrante, and A. Chawla Alternative M2 activation of Kupffer cells by PPAR delta ameliorates obesity-induced insulin resistance Cell Metab 7 2008 496 507
84. A.L. Hevener, J.M. Olefsky, D. Reichart, M.T. Nguyen, G. Bandyopadyhay, H.Y. Leung, M.J. Watt, C. Benner, M.A. Febbraio, A.K. Nguyen, B. Folian, S. Subramaniam, F.J. Gonzalez, C.K. Glass, and M. Ricote Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones J Clin Invest 117 2007 1658 1669
85. A.J. Rickard, J. Morgan, G. Tesch, J.W. Funder, P.J. Fuller, and M.J. Young Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure Hypertension 54 2009 537 543
86. M.G. Usher, S.Z. Duan, C.Y. Ivaschenko, R.A. Frieler, S. Berger, G. Schutz, C.N. Lumeng, and R.M. Mortensen Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice J Clin Invest 120 2010 3350 3364
87. L.A. Bienvenu, J. Morgan, A.J. Rickard, G.H. Tesch, G.A. Cranston, E.K. Fletcher, L.M. Delbridge, and M.J. Young Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis Endocrinology 153 2012 3416 3425
88. K. Labuzek, S. Liber, L. Buldak, G. Machnik, J. Liber, and B. Okopien Eplerenone promotes alternative activation in human monocyte-derived macrophages Pharmacol Rep 65 2013 226 234
89. T. Wada, Y. Miyashita, M. Sasaki, Y. Aruga, Y. Nakamura, Y. Ishii, M. Sasahara, K. Kanasaki, M. Kitada, D. Koya, H. Shimano, H. Tsuneki, and T. Sasaoka Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet Am J Physiol Endocrinol Metab 305 2013 E1415 E1425
90. S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser Aldosterone, mineralocorticoid receptor, and heart failure Mol Cell Endocrinol 350 2012 266 272
91. K.D. Nguyen, Y. Qiu, X. Cui, Y.P. Goh, J. Mwangi, T. David, L. Mukundan, F. Brombacher, R.M. Locksley, and A. Chawla Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis Nature 480 2011 104 108
92. M. Stein, S. Keshav, N. Harris, and S. Gordon Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation J Exp Med 176 1992 287 292
93. T.M. Doherty, R. Kastelein, S. Menon, S. Andrade, and R.L. Coffman Modulation of murine macrophage function by IL-13 J Immunol 151 1993 7151 7160
94. A.G. Doyle, G. Herbein, L.J. Montaner, A.J. Minty, D. Caput, P. Ferrara, and S. Gordon Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma Eur J Immunol 24 1994 1441 1445
95. S.J. Van Dyken, and R.M. Locksley Interleukin-4-and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease Annu Rev Immunol 31 2013 317 343
96. K. Takeda, T. Kishimoto, and S. Akira STAT6: its role in interleukin 4-mediated biological functions J Mol Med (Berl) 75 1997 317 326